Valued at roughly $1.4 billion, the company’s shares have been drawing growing investor attention as its clinical ambitions move closer to reality. MindMed’s shares have been steadily building a strong comeback story over the past few years. Just over the past 52 weeks, shares climbed 83.5%, and momentum has clearly picked up in 2025.Alongside it, MM402, an MDMA-inspired compound, is being explored for autism spectrum disorder, aiming to address core symptoms rather than surface relief. With a pipeline cent ...